The implementation of the agreement of the US government on a loan in the amount of 765 million dollars to Kodak for production of generic drugs is suspended, reports Reuters. The Corporation of financing for international development (DFC) explained that this is due to the recent allegations of the company’s management in wrongdoing.
Earlier, the democratic party has demanded an investigation of transactions with securities that were made by the leaders of Kodak around the time when it became known about the conclusion of an agreement between manufacturer and US authorities.
At the end of July it became known about the agreement between the U.S. government and by Kodak about the production of drugs for the American market. For organization of pharmaceutical production the company had to obtain a state loan in the amount of 765 million dollars. It was assumed that Kodak will be able to provide 25% of all played active pharmaceutical ingredients in the U.S. market.